Global Ischemic stroke Market

Ischemic stroke Comprehensive Study by Surgery Type (Carotid Endarterectomy, Angioplasty, Endovascular Mechanical Thrombectomy, Others), Treatment Type (Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, Antihypertensive, Others), Diagnosis (CT, MRI, Carotid Ultrasound, Cerebral Angiography, Others), End User (Hospital & Clinics, Diagnostic Centre) Players and Region - Global Market Outlook to 2030

Ischemic stroke Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Ischemic stroke
An ischemic stroke occurs when a blood clot, known as a thrombus, blocks or plugs an artery leading to the brain. A blood clot often forms in arteries damaged by a buildup of plaques, known as atherosclerosis. It can occur in the carotid artery of the neck as well as other arteries. The rising prevalence of stroke cases worldwide is a major driver of the ischemic stroke market. Factors such as an aging population, sedentary lifestyles, high blood pressure, diabetes, and obesity increase the incidence of stroke, leading to a higher demand for diagnosis and treatment options.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Competition among existing players is due to the Ischemic stroke market share occupied by leading players. The industry leader is engaged in offering innovative and superior quality products to cater to the ever-growing demand for Ischemic stroke Market. The companies are implementing strategic activities such as acquisitions and mergers along with collaboration with companies in other industries to aid them in improving sustenance and maintaining their competitive advantage. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Ischemic stroke market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bristol Myers Squibb Co. (United States), Roche Holdings AG (Switzerland), Boehringer Ingelheim (Germany), Bayer AG (Germany), Pfizer Inc. (United States), AstraZeneca (United Kingdom), Siemens Healthcare (Germany), Sanofi Plc. (France), Medtronic (Ireland), Boston Scientific (United States), Athersys Inc. (United States) and Bolden Therapeutics (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Astrocyte Pharmaceuticals (United States), NeuExcell Therapeutics (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Ischemic stroke market by and Region.



On the basis of geography, the market of Ischemic stroke has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Surgery Type, the sub-segment i.e. Carotid Endarterectomy will boost the Ischemic stroke market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Tissue Plasminogen Activator will boost the Ischemic stroke market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. CT will boost the Ischemic stroke market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital & Clinics will boost the Ischemic stroke market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing focus on neuroprotective strategies and regenerative therapies for improved stroke recovery.

Market Growth Drivers:
The increasing incidence of chronic diseases. and Increasing incidence of ischemic stroke cases particularly in aging population.

Challenges:
Complications associated with treatments.

Restraints:
High cost associated with advanced imaging techniques and specialized treatments. and Limited accessibility to stroke centre and specialized stroke care.

Opportunities:
Integration of artificial intelligence and machine learning in stroke diagnosis. and Development of innovative therapies, including thrombolytic agent.

Market Leaders and their expansionary development strategies
In May 2021, Biogen Inc. and TMS Co., Ltd. announced that Biogen acquired TMS-007, an investigational drug for acute ischemic stroke, from TMS. Biogen’s decision to acquire TMS-007 was based on positive data from a Phase 2a study. The study met its primary safety objective with no incidence of symptomatic intracranial haemorrhage (sICH) and demonstrated positive impacts on both blood vessel reopening in the brain as well as patient functional recovery.
In October 2020, Cerenovus, part of Johnson & Johnson Medical Devices Companies, has announced the European launch of Cerenovus Nimbus designed to remove tough clots for successful revascularisation in patients with acute ischemic stroke caused by a large vessel occlusion.


Key Target Audience
Manufacturers Suppliers and Distributors, Venture Capitalists and Private Equity Firms, New Entrants/Investors, Strategic Business Planners, Government Regulatory, Research Organizations, End-Use Industries and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Surgery Type
  • Carotid Endarterectomy
  • Angioplasty
  • Endovascular Mechanical Thrombectomy
  • Others

By Treatment Type
  • Tissue Plasminogen Activator
  • Anticoagulant
  • Antiplatelet
  • Antihypertensive
  • Others

By Diagnosis
  • CT
  • MRI
  • Carotid Ultrasound
  • Cerebral Angiography
  • Others

By End User
  • Hospital & Clinics
  • Diagnostic Centre

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The increasing incidence of chronic diseases.
      • 3.2.2. Increasing incidence of ischemic stroke cases particularly in aging population.
    • 3.3. Market Challenges
      • 3.3.1. Complications associated with treatments.
    • 3.4. Market Trends
      • 3.4.1. Increasing focus on neuroprotective strategies and regenerative therapies for improved stroke recovery.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ischemic stroke, by Surgery Type, Treatment Type, Diagnosis, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Ischemic stroke (Value)
      • 5.2.1. Global Ischemic stroke by: Surgery Type (Value)
        • 5.2.1.1. Carotid Endarterectomy
        • 5.2.1.2. Angioplasty
        • 5.2.1.3. Endovascular Mechanical Thrombectomy
        • 5.2.1.4. Others
      • 5.2.2. Global Ischemic stroke by: Treatment Type (Value)
        • 5.2.2.1. Tissue Plasminogen Activator
        • 5.2.2.2. Anticoagulant
        • 5.2.2.3. Antiplatelet
        • 5.2.2.4. Antihypertensive
        • 5.2.2.5. Others
      • 5.2.3. Global Ischemic stroke by: Diagnosis (Value)
        • 5.2.3.1. CT
        • 5.2.3.2. MRI
        • 5.2.3.3. Carotid Ultrasound
        • 5.2.3.4. Cerebral Angiography
        • 5.2.3.5. Others
      • 5.2.4. Global Ischemic stroke by: End User (Value)
        • 5.2.4.1. Hospital & Clinics
        • 5.2.4.2. Diagnostic Centre
      • 5.2.5. Global Ischemic stroke Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Ischemic stroke: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol Myers Squibb Co. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche Holdings AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boehringer Ingelheim (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Siemens Healthcare (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi Plc. (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Medtronic (Ireland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Boston Scientific (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Athersys Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Bolden Therapeutics (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Ischemic stroke Sale, by Surgery Type, Treatment Type, Diagnosis, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Ischemic stroke (Value)
      • 7.2.1. Global Ischemic stroke by: Surgery Type (Value)
        • 7.2.1.1. Carotid Endarterectomy
        • 7.2.1.2. Angioplasty
        • 7.2.1.3. Endovascular Mechanical Thrombectomy
        • 7.2.1.4. Others
      • 7.2.2. Global Ischemic stroke by: Treatment Type (Value)
        • 7.2.2.1. Tissue Plasminogen Activator
        • 7.2.2.2. Anticoagulant
        • 7.2.2.3. Antiplatelet
        • 7.2.2.4. Antihypertensive
        • 7.2.2.5. Others
      • 7.2.3. Global Ischemic stroke by: Diagnosis (Value)
        • 7.2.3.1. CT
        • 7.2.3.2. MRI
        • 7.2.3.3. Carotid Ultrasound
        • 7.2.3.4. Cerebral Angiography
        • 7.2.3.5. Others
      • 7.2.4. Global Ischemic stroke by: End User (Value)
        • 7.2.4.1. Hospital & Clinics
        • 7.2.4.2. Diagnostic Centre
      • 7.2.5. Global Ischemic stroke Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ischemic stroke: by Surgery Type(USD Million)
  • Table 2. Ischemic stroke Carotid Endarterectomy , by Region USD Million (2018-2023)
  • Table 3. Ischemic stroke Angioplasty , by Region USD Million (2018-2023)
  • Table 4. Ischemic stroke Endovascular Mechanical Thrombectomy , by Region USD Million (2018-2023)
  • Table 5. Ischemic stroke Others , by Region USD Million (2018-2023)
  • Table 6. Ischemic stroke: by Treatment Type(USD Million)
  • Table 7. Ischemic stroke Tissue Plasminogen Activator , by Region USD Million (2018-2023)
  • Table 8. Ischemic stroke Anticoagulant , by Region USD Million (2018-2023)
  • Table 9. Ischemic stroke Antiplatelet , by Region USD Million (2018-2023)
  • Table 10. Ischemic stroke Antihypertensive , by Region USD Million (2018-2023)
  • Table 11. Ischemic stroke Others , by Region USD Million (2018-2023)
  • Table 12. Ischemic stroke: by Diagnosis(USD Million)
  • Table 13. Ischemic stroke CT , by Region USD Million (2018-2023)
  • Table 14. Ischemic stroke MRI , by Region USD Million (2018-2023)
  • Table 15. Ischemic stroke Carotid Ultrasound , by Region USD Million (2018-2023)
  • Table 16. Ischemic stroke Cerebral Angiography , by Region USD Million (2018-2023)
  • Table 17. Ischemic stroke Others , by Region USD Million (2018-2023)
  • Table 18. Ischemic stroke: by End User(USD Million)
  • Table 19. Ischemic stroke Hospital & Clinics , by Region USD Million (2018-2023)
  • Table 20. Ischemic stroke Diagnostic Centre , by Region USD Million (2018-2023)
  • Table 21. South America Ischemic stroke, by Country USD Million (2018-2023)
  • Table 22. South America Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 23. South America Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 24. South America Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 25. South America Ischemic stroke, by End User USD Million (2018-2023)
  • Table 26. Brazil Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 27. Brazil Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 28. Brazil Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 29. Brazil Ischemic stroke, by End User USD Million (2018-2023)
  • Table 30. Argentina Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 31. Argentina Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 32. Argentina Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 33. Argentina Ischemic stroke, by End User USD Million (2018-2023)
  • Table 34. Rest of South America Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 35. Rest of South America Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 36. Rest of South America Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 37. Rest of South America Ischemic stroke, by End User USD Million (2018-2023)
  • Table 38. Asia Pacific Ischemic stroke, by Country USD Million (2018-2023)
  • Table 39. Asia Pacific Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 40. Asia Pacific Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 41. Asia Pacific Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 42. Asia Pacific Ischemic stroke, by End User USD Million (2018-2023)
  • Table 43. China Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 44. China Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 45. China Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 46. China Ischemic stroke, by End User USD Million (2018-2023)
  • Table 47. Japan Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 48. Japan Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 49. Japan Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 50. Japan Ischemic stroke, by End User USD Million (2018-2023)
  • Table 51. India Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 52. India Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 53. India Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 54. India Ischemic stroke, by End User USD Million (2018-2023)
  • Table 55. South Korea Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 56. South Korea Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 57. South Korea Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 58. South Korea Ischemic stroke, by End User USD Million (2018-2023)
  • Table 59. Taiwan Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 60. Taiwan Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 61. Taiwan Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 62. Taiwan Ischemic stroke, by End User USD Million (2018-2023)
  • Table 63. Australia Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 64. Australia Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 65. Australia Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 66. Australia Ischemic stroke, by End User USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Ischemic stroke, by End User USD Million (2018-2023)
  • Table 71. Europe Ischemic stroke, by Country USD Million (2018-2023)
  • Table 72. Europe Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 73. Europe Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 74. Europe Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 75. Europe Ischemic stroke, by End User USD Million (2018-2023)
  • Table 76. Germany Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 77. Germany Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 78. Germany Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 79. Germany Ischemic stroke, by End User USD Million (2018-2023)
  • Table 80. France Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 81. France Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 82. France Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 83. France Ischemic stroke, by End User USD Million (2018-2023)
  • Table 84. Italy Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 85. Italy Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 86. Italy Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 87. Italy Ischemic stroke, by End User USD Million (2018-2023)
  • Table 88. United Kingdom Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 89. United Kingdom Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 90. United Kingdom Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 91. United Kingdom Ischemic stroke, by End User USD Million (2018-2023)
  • Table 92. Netherlands Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 93. Netherlands Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 94. Netherlands Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 95. Netherlands Ischemic stroke, by End User USD Million (2018-2023)
  • Table 96. Rest of Europe Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 97. Rest of Europe Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 98. Rest of Europe Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 99. Rest of Europe Ischemic stroke, by End User USD Million (2018-2023)
  • Table 100. MEA Ischemic stroke, by Country USD Million (2018-2023)
  • Table 101. MEA Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 102. MEA Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 103. MEA Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 104. MEA Ischemic stroke, by End User USD Million (2018-2023)
  • Table 105. Middle East Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 106. Middle East Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 107. Middle East Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 108. Middle East Ischemic stroke, by End User USD Million (2018-2023)
  • Table 109. Africa Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 110. Africa Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 111. Africa Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 112. Africa Ischemic stroke, by End User USD Million (2018-2023)
  • Table 113. North America Ischemic stroke, by Country USD Million (2018-2023)
  • Table 114. North America Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 115. North America Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 116. North America Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 117. North America Ischemic stroke, by End User USD Million (2018-2023)
  • Table 118. United States Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 119. United States Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 120. United States Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 121. United States Ischemic stroke, by End User USD Million (2018-2023)
  • Table 122. Canada Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 123. Canada Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 124. Canada Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 125. Canada Ischemic stroke, by End User USD Million (2018-2023)
  • Table 126. Mexico Ischemic stroke, by Surgery Type USD Million (2018-2023)
  • Table 127. Mexico Ischemic stroke, by Treatment Type USD Million (2018-2023)
  • Table 128. Mexico Ischemic stroke, by Diagnosis USD Million (2018-2023)
  • Table 129. Mexico Ischemic stroke, by End User USD Million (2018-2023)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Ischemic stroke: by Surgery Type(USD Million)
  • Table 143. Ischemic stroke Carotid Endarterectomy , by Region USD Million (2025-2030)
  • Table 144. Ischemic stroke Angioplasty , by Region USD Million (2025-2030)
  • Table 145. Ischemic stroke Endovascular Mechanical Thrombectomy , by Region USD Million (2025-2030)
  • Table 146. Ischemic stroke Others , by Region USD Million (2025-2030)
  • Table 147. Ischemic stroke: by Treatment Type(USD Million)
  • Table 148. Ischemic stroke Tissue Plasminogen Activator , by Region USD Million (2025-2030)
  • Table 149. Ischemic stroke Anticoagulant , by Region USD Million (2025-2030)
  • Table 150. Ischemic stroke Antiplatelet , by Region USD Million (2025-2030)
  • Table 151. Ischemic stroke Antihypertensive , by Region USD Million (2025-2030)
  • Table 152. Ischemic stroke Others , by Region USD Million (2025-2030)
  • Table 153. Ischemic stroke: by Diagnosis(USD Million)
  • Table 154. Ischemic stroke CT , by Region USD Million (2025-2030)
  • Table 155. Ischemic stroke MRI , by Region USD Million (2025-2030)
  • Table 156. Ischemic stroke Carotid Ultrasound , by Region USD Million (2025-2030)
  • Table 157. Ischemic stroke Cerebral Angiography , by Region USD Million (2025-2030)
  • Table 158. Ischemic stroke Others , by Region USD Million (2025-2030)
  • Table 159. Ischemic stroke: by End User(USD Million)
  • Table 160. Ischemic stroke Hospital & Clinics , by Region USD Million (2025-2030)
  • Table 161. Ischemic stroke Diagnostic Centre , by Region USD Million (2025-2030)
  • Table 162. South America Ischemic stroke, by Country USD Million (2025-2030)
  • Table 163. South America Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 164. South America Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 165. South America Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 166. South America Ischemic stroke, by End User USD Million (2025-2030)
  • Table 167. Brazil Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 168. Brazil Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 169. Brazil Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 170. Brazil Ischemic stroke, by End User USD Million (2025-2030)
  • Table 171. Argentina Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 172. Argentina Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 173. Argentina Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 174. Argentina Ischemic stroke, by End User USD Million (2025-2030)
  • Table 175. Rest of South America Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 176. Rest of South America Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 177. Rest of South America Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 178. Rest of South America Ischemic stroke, by End User USD Million (2025-2030)
  • Table 179. Asia Pacific Ischemic stroke, by Country USD Million (2025-2030)
  • Table 180. Asia Pacific Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 181. Asia Pacific Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 182. Asia Pacific Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 183. Asia Pacific Ischemic stroke, by End User USD Million (2025-2030)
  • Table 184. China Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 185. China Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 186. China Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 187. China Ischemic stroke, by End User USD Million (2025-2030)
  • Table 188. Japan Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 189. Japan Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 190. Japan Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 191. Japan Ischemic stroke, by End User USD Million (2025-2030)
  • Table 192. India Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 193. India Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 194. India Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 195. India Ischemic stroke, by End User USD Million (2025-2030)
  • Table 196. South Korea Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 197. South Korea Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 198. South Korea Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 199. South Korea Ischemic stroke, by End User USD Million (2025-2030)
  • Table 200. Taiwan Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 201. Taiwan Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 202. Taiwan Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 203. Taiwan Ischemic stroke, by End User USD Million (2025-2030)
  • Table 204. Australia Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 205. Australia Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 206. Australia Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 207. Australia Ischemic stroke, by End User USD Million (2025-2030)
  • Table 208. Rest of Asia-Pacific Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 209. Rest of Asia-Pacific Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 210. Rest of Asia-Pacific Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 211. Rest of Asia-Pacific Ischemic stroke, by End User USD Million (2025-2030)
  • Table 212. Europe Ischemic stroke, by Country USD Million (2025-2030)
  • Table 213. Europe Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 214. Europe Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 215. Europe Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 216. Europe Ischemic stroke, by End User USD Million (2025-2030)
  • Table 217. Germany Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 218. Germany Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 219. Germany Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 220. Germany Ischemic stroke, by End User USD Million (2025-2030)
  • Table 221. France Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 222. France Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 223. France Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 224. France Ischemic stroke, by End User USD Million (2025-2030)
  • Table 225. Italy Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 226. Italy Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 227. Italy Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 228. Italy Ischemic stroke, by End User USD Million (2025-2030)
  • Table 229. United Kingdom Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 230. United Kingdom Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 231. United Kingdom Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 232. United Kingdom Ischemic stroke, by End User USD Million (2025-2030)
  • Table 233. Netherlands Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 234. Netherlands Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 235. Netherlands Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 236. Netherlands Ischemic stroke, by End User USD Million (2025-2030)
  • Table 237. Rest of Europe Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 238. Rest of Europe Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 239. Rest of Europe Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 240. Rest of Europe Ischemic stroke, by End User USD Million (2025-2030)
  • Table 241. MEA Ischemic stroke, by Country USD Million (2025-2030)
  • Table 242. MEA Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 243. MEA Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 244. MEA Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 245. MEA Ischemic stroke, by End User USD Million (2025-2030)
  • Table 246. Middle East Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 247. Middle East Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 248. Middle East Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 249. Middle East Ischemic stroke, by End User USD Million (2025-2030)
  • Table 250. Africa Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 251. Africa Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 252. Africa Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 253. Africa Ischemic stroke, by End User USD Million (2025-2030)
  • Table 254. North America Ischemic stroke, by Country USD Million (2025-2030)
  • Table 255. North America Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 256. North America Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 257. North America Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 258. North America Ischemic stroke, by End User USD Million (2025-2030)
  • Table 259. United States Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 260. United States Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 261. United States Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 262. United States Ischemic stroke, by End User USD Million (2025-2030)
  • Table 263. Canada Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 264. Canada Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 265. Canada Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 266. Canada Ischemic stroke, by End User USD Million (2025-2030)
  • Table 267. Mexico Ischemic stroke, by Surgery Type USD Million (2025-2030)
  • Table 268. Mexico Ischemic stroke, by Treatment Type USD Million (2025-2030)
  • Table 269. Mexico Ischemic stroke, by Diagnosis USD Million (2025-2030)
  • Table 270. Mexico Ischemic stroke, by End User USD Million (2025-2030)
  • Table 271. Research Programs/Design for This Report
  • Table 272. Key Data Information from Secondary Sources
  • Table 273. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ischemic stroke: by Surgery Type USD Million (2018-2023)
  • Figure 5. Global Ischemic stroke: by Treatment Type USD Million (2018-2023)
  • Figure 6. Global Ischemic stroke: by Diagnosis USD Million (2018-2023)
  • Figure 7. Global Ischemic stroke: by End User USD Million (2018-2023)
  • Figure 8. South America Ischemic stroke Share (%), by Country
  • Figure 9. Asia Pacific Ischemic stroke Share (%), by Country
  • Figure 10. Europe Ischemic stroke Share (%), by Country
  • Figure 11. MEA Ischemic stroke Share (%), by Country
  • Figure 12. North America Ischemic stroke Share (%), by Country
  • Figure 13. Global Ischemic stroke share by Players 2023 (%)
  • Figure 14. Global Ischemic stroke share by Players (Top 3) 2023(%)
  • Figure 15. Global Ischemic stroke share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Bristol Myers Squibb Co. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Bristol Myers Squibb Co. (United States) Revenue: by Geography 2023
  • Figure 19. Roche Holdings AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Roche Holdings AG (Switzerland) Revenue: by Geography 2023
  • Figure 21. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Boehringer Ingelheim (Germany) Revenue: by Geography 2023
  • Figure 23. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 25. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 27. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 29. Siemens Healthcare (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Siemens Healthcare (Germany) Revenue: by Geography 2023
  • Figure 31. Sanofi Plc. (France) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi Plc. (France) Revenue: by Geography 2023
  • Figure 33. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 34. Medtronic (Ireland) Revenue: by Geography 2023
  • Figure 35. Boston Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 36. Boston Scientific (United States) Revenue: by Geography 2023
  • Figure 37. Athersys Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Athersys Inc. (United States) Revenue: by Geography 2023
  • Figure 39. Bolden Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 40. Bolden Therapeutics (United States) Revenue: by Geography 2023
  • Figure 41. Global Ischemic stroke: by Surgery Type USD Million (2025-2030)
  • Figure 42. Global Ischemic stroke: by Treatment Type USD Million (2025-2030)
  • Figure 43. Global Ischemic stroke: by Diagnosis USD Million (2025-2030)
  • Figure 44. Global Ischemic stroke: by End User USD Million (2025-2030)
  • Figure 45. South America Ischemic stroke Share (%), by Country
  • Figure 46. Asia Pacific Ischemic stroke Share (%), by Country
  • Figure 47. Europe Ischemic stroke Share (%), by Country
  • Figure 48. MEA Ischemic stroke Share (%), by Country
  • Figure 49. North America Ischemic stroke Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bristol Myers Squibb Co. (United States)
  • Roche Holdings AG (Switzerland)
  • Boehringer Ingelheim (Germany)
  • Bayer AG (Germany)
  • Pfizer Inc. (United States)
  • AstraZeneca (United Kingdom)
  • Siemens Healthcare (Germany)
  • Sanofi Plc. (France)
  • Medtronic (Ireland)
  • Boston Scientific (United States)
  • Athersys Inc. (United States)
  • Bolden Therapeutics (United States)
Additional players considered in the study are as follows:
Astrocyte Pharmaceuticals (United States) , NeuExcell Therapeutics (United States) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 216 Pages 78 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Ischemic stroke Market Quantitative research analysis
Global Ischemic stroke Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bristol Myers Squibb Co. (United States), Roche Holdings AG (Switzerland), Boehringer Ingelheim (Germany), Bayer AG (Germany), Pfizer Inc. (United States), AstraZeneca (United Kingdom), Siemens Healthcare (Germany), Sanofi Plc. (France), Medtronic (Ireland), Boston Scientific (United States), Athersys Inc. (United States) and Bolden Therapeutics (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing focus on neuroprotective strategies and regenerative therapies for improved stroke recovery." is seen as one of major influencing trends for Ischemic stroke Market during projected period 2023-2030.
The Ischemic stroke market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Ischemic stroke Market Report?

Have a Query? Click Here

Other Related Reports

Cardiovascular Application Comprehensive Study by Type (Diagnostic and Monitoring Devices, (Electrocardiogram, Holter Monitors, Event Monitors, Others), Interventional Devices, (Coronary Stents, Cath...
$ 3800
Membranous Nephropathy Comprehensive Study by Type (Primary Membranous Nephropathy (Idiopathic), Secondary Membranous Nephropathy), Age Group (Children, Adults), Treatment Type (Biologics, Pharmaceut...
$ 3800
Malocclusion Comprehensive Study by Type (Overcrowding, Spacing, Openbite, Overjet, Overbite, Underbite, Crossbite, Diastema, Impacted Tooth, Missing Tooth), Age Group (Children, Adults), Treatment T...
$ 3800
Orphan Diseases Comprehensive Study by Disease Type (Oncology, Allergic and Immunologic Disorders, Cardiac and Vascular Conditions, Infectious Diseases, Neurologic Conditions, Skin and Soft Tissue Co...
$ 3800